Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors.
Kyung Hae JungPatricia LoRussoHoward BurrisMichael GordonYung-Jue BangMatthew D HellmannAndres CervantesMaria Ochoa de OlzaAurelien MarabelleF Stephen HodiMyung-Ju AhnLeisha A EmensFabrice BarlesiOmid HamidEmiliano CalvoDavid McDermottHatem SolimanIna RheeRay LinTony PourmohamadJulia SuchomelAmy TsuhakoKari MorrisseySami MahrusRoland MorleyAndrea PirzkallS Lindsey DavisPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)
The combination of navoximod and atezolizumab demonstrated acceptable safety, tolerability, and pharmacokinetics for patients with advanced cancer. Although activity was observed, there was no clear evidence of benefit from adding navoximod to atezolizumab.